Sativex® as Add-on therapy Vs. further optimized first-line ANTispastics (SAVANT) in resistant multiple sclerosis spasticity: a double-blind, placebo-controlled randomised clinical trial
Markovà, Jolana, Essner, Ute, Akmaz, Bülent, Marinelli, Marcella, Trompke, Christiane, Lentschat, Arnd, Silván, Carlos VilaLanguage:
english
Journal:
International Journal of Neuroscience
DOI:
10.1080/00207454.2018.1481066
Date:
May, 2018
File:
PDF, 941 KB
english, 2018